Epigenetic editing to advance CAR T cell therapy

Area of Science:

• Immunology
• Cancer Biology
• Epigenetics

Background:

• Chimeric antigen receptor (CAR) T cell therapy shows promise for cancer treatment but faces challenges like limited durable responses and overcoming immunosuppressive tumor microenvironments.
• T cell exhaustion and differentiation into short-lived effector cells are key limitations impacting CAR T cell efficacy.
• Epigenetic modifications critically influence T cell function, persistence, and exhaustion, presenting a target for therapeutic enhancement.

Purpose of the Study:

• To review the role of epigenetic regulation in CAR T cell biology and therapy.
• To explore how epigenetic drugs, genetic interventions, and epigenetic editing can improve CAR T cell potency, persistence, and accessibility.
• To highlight epigenetic editing as a next-generation approach for precise and durable reprogramming of CAR T cells.

Main Methods:

• Review of existing literature on epigenetic regulation in T cell biology and CAR T cell therapy.
• Analysis of studies investigating epigenetic regulators (e.g., TET2, DNMT3A) and their impact on CAR T cell function.
• Examination of gene-targeted epigenetic editing strategies for modulating CAR T cell phenotypes and silencing immune rejection pathways.

Main Results:

• Inhibiting epigenetic regulators like TET2 or DNMT3A can promote memory-like, non-exhausted CAR T cell states with enhanced antitumor activity.
• Epigenetic editing allows for precise, durable, and reversible gene expression reprogramming without DNA breaks, demonstrated by silencing inhibitory receptors (PD-1, LAG-3).
• Epigenetic editing can facilitate the development of off-the-shelf CAR T cells by silencing immune rejection pathways.

Conclusions:

• Epigenetic regulation is pivotal in shaping CAR T cell persistence and therapeutic efficacy.
• Epigenetic editing represents a powerful strategy to generate more potent, persistent, and broadly applicable CAR T cell therapies.
• Harnessing epigenetic modifications offers a path to overcome current limitations and improve clinical translation of CAR T cell therapy for various cancers.